Fetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia

被引:7
|
作者
Eridani, Sandro [1 ]
Mosca, Andrea [1 ]
机构
[1] Univ Milan, Dept Biomed Sci & Technol, Via Fratelli Cervi 93, I-20090 Milan, Italy
来源
关键词
sickle cell disease; hemoglobin F; determinants; inducers; cell engineering; induced pluripotent stem cells;
D O I
10.2147/JBM.S14942
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The natural history of severe hemoglobinopathies like sickle cell disease (SCD) is rather variable, depending on the circumstances, but the main influence on such variability is the level of fetal hemoglobin (HbF) in the patient's red cells. It is well known that a significant HbF level is associated with a milder course of disease and fewer complications. Therefore, attempts have been made to reactivate using various means the HbF production, which is normally switched off perinatally. A pharmacological approach has been attempted since the 1980s, ranging from drugs like 5-azacytidine and its derivative, decitabine, to a series of compounds like hydroxyurea and a number of histone deacetylase inhibitors like butyrate, which seem to act as epigenetic modifiers. Many other disparate agents have been tried with mixed results, but hydroxyurea remains the most effective compound so far available. Combinations of different compounds have also been tried with some success. Established treatments like bone marrow or cord blood transplantation are so far the only real cure for a limited number of patients with severe hemoglobinopathies. Improved chemotherapy regimens of milder toxicity than those employed in the past have made it possible recently to obtain a stable, mixed donor-recipient chimerism, with reversal of the SCD phenotype. However, great effort is directed to cell engineering, searching for an effective gene vector by which a desired gene can be transferred into new classes of vectors for autologous hemopoietic stem cells. Recent studies are also aiming at targeted insertion of the therapeutic gene into hemopoietic cells, which can also be "induced"human stem cells, obtained from somatic dedifferentiated cells. Attention in this area must be paid to the possibility of undesired effects, like the emergence of potentially oncogenic cell populations. Finally, an update is presented on improved HbF determination methods, because common international standards are becoming mandatory.
引用
收藏
页码:23 / 30
页数:8
相关论文
共 50 条
  • [1] Fetal hemoglobin in sickle cell anemia
    Nadkarni, Anita
    Dabke, Pooja
    Colah, Roshan B.
    Ghosh, K.
    BLOOD CELLS MOLECULES AND DISEASES, 2014, 52 (04) : 175 - 175
  • [2] Fetal hemoglobin in sickle cell anemia
    Steinberg, Martin H.
    BLOOD, 2020, 136 (21) : 2392 - 2400
  • [3] Fetal hemoglobin in sickle cell anemia
    Akinsheye, Idowu
    Alsultan, Abdulrahman
    Solovieff, Nadia
    Duyen Ngo
    Baldwin, Clinton T.
    Sebastiani, Paola
    Chui, David H. K.
    Steinberg, Martin H.
    BLOOD, 2011, 118 (01) : 19 - 27
  • [5] SICKLE-CELL-ANEMIA AND FETAL HEMOGLOBIN
    STEINBERG, MH
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1994, 308 (05): : 259 - 265
  • [6] Modulation of fetal hemoglobin in sickle cell anemia
    Steinberg, MH
    HEMOGLOBIN, 2001, 25 (02) : 195 - 211
  • [7] "Packaging" of fetal hemoglobin in sickle cell anemia
    Buchanan, George R.
    BLOOD, 2014, 123 (04) : 464 - 465
  • [8] FETAL HEMOGLOBIN IN SICKLE-CELL-ANEMIA
    OZSOYLU, S
    PEDIATRIC RESEARCH, 1979, 13 (08) : 956 - 956
  • [9] Reactivation of fetal hemoglobin in thalassemia and sickle cell disease
    Eridani, Sandro
    Avemaria, Francesca
    Mosca, Andrea
    THALASSEMIA REPORTS, 2014, 4 (02) : 55 - 61
  • [10] FLUCTUATION OF FETAL HEMOGLOBIN IN SICKLE-CELL ANEMIA
    MORRISON, JC
    WHYBREW, WD
    BUCOVAZ, ET
    WISER, WL
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1976, 125 (08) : 1085 - 1088